NASDAQ:AQXPAquinox Pharmaceuticals Stock Price, Forecast & News Notice: This company has been marked as potentially delisted and may not be actively trading. Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Aquinox Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $12.16 -0.08 (-0.65 %) (As of 05/26/2020 04:00 PM ET) Add Compare Share Today's Range$11.95Now: $12.16▼$12.8550-Day Range$3.68MA: $3.94▼$4.0352-Week Range$2.00Now: $12.16▼$3.84Volume247,121 shsAverage Volume239,362 shsMarket Capitalization$286.25 millionP/E RatioN/ADividend YieldN/ABeta-7.37 ProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Aquinox Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in developing novel therapeutics for chronic urological conditions by inflammation and pain. The company focuses on a library of novel compounds that activate SH2-containing inositol-5'-phosphatase 1 (SHIP1) to develop therapeutics for application in inflammation, inflammatory pain, and blood cancers. Its lead product candidate is Rosiptor (Leadership 301), a small molecule activator of SHIP1 that is in Phase III clinical trials for treatment in interstitial cystitis/bladder pain syndrome. The company was formerly known as Aquinox Pharmaceuticals (USA) Inc. and changed its name to Aquinox Pharmaceuticals, Inc. in January 2014. Aquinox Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Vancouver, Canada.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Aquinox Pharmaceuticals. Previous Next 2.8 Community Rank Outperform VotesAquinox Pharmaceuticals has received 299 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAquinox Pharmaceuticals has received 235 “underperform” votes. (Add your “underperform” vote.)Community SentimentAquinox Pharmaceuticals has received 55.99% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Aquinox Pharmaceuticals and other stocks. Vote “Outperform” if you believe AQXP will outperform the S&P 500 over the long term. Vote “Underperform” if you believe AQXP will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAquinox Pharmaceuticals does not currently pay a dividend.Dividend GrowthAquinox Pharmaceuticals does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aquinox Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.00% of the stock of Aquinox Pharmaceuticals is held by insiders.Percentage Held by Institutions71.69% of the stock of Aquinox Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Price to Book Value per Share RatioAquinox Pharmaceuticals has a P/B Ratio of 3.94. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.76 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AQXP Previous Symbol CUSIPN/A CIK1404644 Webwww.aqxpharma.com Phone604-629-9223Debt Debt-to-Equity RatioN/A Current Ratio63.17 Quick Ratio63.17Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$25 million Price / Sales11.45 Cash FlowN/A Price / Cash FlowN/A Book Value$3.09 per share Price / Book3.94Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-31,580,000.00 Net MarginsN/A Return on Equity-30.13% Return on Assets-28.08%Miscellaneous Employees8 Outstanding Shares23,540,000Market Cap$286.25 million Next Earnings DateN/A OptionableOptionable Receive AQXP News and Ratings via Email Sign-up to receive the latest news and ratings for AQXP and its competitors with MarketBeat's FREE daily newsletter. Aquinox Pharmaceuticals (NASDAQ:AQXP) Frequently Asked Questions How were Aquinox Pharmaceuticals' earnings last quarter? Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) announced its quarterly earnings data on Thursday, November, 8th. The company reported ($0.64) EPS for the quarter, missing the Zacks' consensus estimate of ($0.21) by $0.43. View Aquinox Pharmaceuticals' earnings history. Has Aquinox Pharmaceuticals been receiving favorable news coverage? Media coverage about AQXP stock has been trending somewhat negative this week, according to InfoTrie Sentiment Analysis. InfoTrie rates the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Aquinox Pharmaceuticals earned a news sentiment score of -1.9 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near term. View the latest news aboutAquinox Pharmaceuticals. Who are some of Aquinox Pharmaceuticals' key competitors? Some companies that are related to Aquinox Pharmaceuticals include Myovant Sciences (MYOV), I-Mab (ARQT), Enanta Pharmaceuticals (ENTA), Aimmune Therapeutics (AIMT), Rocket Pharmaceuticals (RCKT), Applied Therapeutics (APLT), BioXcel Therapeutics (BTAI), Phibro Animal Health (PAHC), Odonate Therapeutics (ODT), Stoke Therapeutics (STOK), NextCure (NXTC), Athenex (ATNX), Rhythm Pharmaceuticals (RYTM), ImmunoGen (IMGN) and Endo International (ENDP). View all competitors. What other stocks do shareholders of Aquinox Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aquinox Pharmaceuticals investors own include Novavax (NVAX), Bausch Health Companies (BHC), Sarepta Therapeutics (SRPT), Gilead Sciences (GILD), XOMA (XOMA), Sodastream International (SODA), ZIOPHARM Oncology (ZIOP), ACADIA Pharmaceuticals (ACAD), Alnylam Pharmaceuticals (ALNY) and Century Aluminum (CENX). Who are Aquinox Pharmaceuticals' key executives? Aquinox Pharmaceuticals' management team includes the following people: Mr. David J. Main, Co-Founder, Chairman, CEO & Pres (Age 54)Mr. Kamran Alam, CFO, VP of Fin. & Corp. Sec. (Age 45)Ms. Shelley McCloskey, VP of HR & Admin. (Age 59) What is Aquinox Pharmaceuticals' stock symbol? Aquinox Pharmaceuticals trades on the NASDAQ under the ticker symbol "AQXP." What is Aquinox Pharmaceuticals' stock price today? One share of AQXP stock can currently be purchased for approximately $12.16. How big of a company is Aquinox Pharmaceuticals? Aquinox Pharmaceuticals has a market capitalization of $286.25 million and generates $25 million in revenue each year. Aquinox Pharmaceuticals employs 8 workers across the globe. What is Aquinox Pharmaceuticals' official website? The official website for Aquinox Pharmaceuticals is www.aqxpharma.com. How can I contact Aquinox Pharmaceuticals? Aquinox Pharmaceuticals' mailing address is 450-887 GREAT NORTHERN WAY, VANCOUVER A1, V5T 4T5. The company can be reached via phone at 604-629-9223 or via email at [email protected] This page was last updated on 5/27/2020 by MarketBeat.com Staff
